Thallion Receives Health Canada Approval to Initiate Phase II Study for TLN-232 in Metastatic Melanoma Patients
Company initiates Phase II study with its second oncology product Thallion Pharmaceuticals Inc. (TSX: TLN) today announced it has received authorization from the Therapeutic Products Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-232 as a treatment for metastatic melanoma in patients that have failed at least one prior therapy. The TLN-232 trial is the second Phase II study to be initiated this year from Thallion\'s oncology pipeline
\"We have now moved both of our oncology product candidates into Phase II efficacy trials this year. Our recent progress provides us with a deeper, more balanced pipeline of late-stage opportunities in multiple indications,\" said Lloyd M. Segal, Chief Executive Officer of Thallion Pharmaceuticals Inc.
- Published: 26 June 2008
- Written by Editor